β1受体阻滞剂防治脓毒症心肌病作用的研究进展  

Research progress in the effect ofβ1-receptor blockers on prevention and treatment of sepsis-induced cardiomyopathy

作　　者：胡盛惠 姚立影 魏薇[2] 高岩[2] HU Shenghui;YAO Liying;WEI Wei;GAO Yan(Graduate School,the Fourth Affiliated Hospital of Harbin Medical University,Heilongjiang 150001,China;Department of Critical Care Medicine,the Fourth Affiliated Hospital of Harbin Medical University,Heilongjiang 150001,China)

机构地区：[1]哈尔滨医科大学附属第四医院研究生院,黑龙江150001 [2]哈尔滨医科大学附属第四医院重症医学科,黑龙江150001

出　　处：《中国临床新医学》2024年第2期227-232,共6页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：吴阶平医学基金会临床科研专项课题(编号:32067502021084)。

摘　　要：脓毒症心肌病是脓毒症引起的可逆性心肌损伤,是一种非缺血性急性心功能障碍,可显著增加脓毒症患者的病死率。β1受体阻滞剂具有抗应激、抗氧化、调节免疫和抑制细胞死亡及保护心肌的作用。该文对β1受体阻滞剂防治脓毒症心肌病作用的研究进展作一综述。Sepsis-induced cardiomyopathy(SIC)is a reversible myocardial injury caused by sepsis.It is a non-ischemic acute cardiac dysfunction that can significantly increase the mortality rate of sepsis patients,andβ1-receptor blockers have anti-stress,anti-oxidation,immune regulation and cell death inhibition effects,and have potential protective effects on myocardia.This paper reviews the research progress in the effect ofβ1-receptor blockers on prevention and treatment of SIC.

关 键 词：脓毒症 脓毒症心肌病 Β1受体阻滞剂 艾司洛尔 药理作用 

分 类 号：R453.9[医药卫生—治疗学]